All In Biotech

Drug Trial Radar · NCT06589986

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Sep 17, 2024

Primary completion

Jan 30, 2027

Study completion Jan 30, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

Conditions

  • Moderately to Severely Active Ulcerative Colitis

Interventions

  • AfimkibartDrug

    Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

  • PlaceboDrug

    Placebo matching IV afimkibart. Placebo matching SC afimkibart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Clinical Remission at Week 12Time frame: At Week 12
  2. Percentage of Participants with Clinical Remission at Week 52Time frame: At Week 52

Locations

184 sites in 30 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan

    Dothan, Alabama

  • Om Research LLC

    Lancaster, California

  • University of California Irvine

    Orange, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Access Research Institute

    Brooksville, Florida

  • Gastro Florida

    Clearwater, Florida

  • Clinical Research of Osceola, LLC

    Kissimmee, Florida

  • Auzmer Research

    Lakeland, Florida

  • Florida Research Institute - Lakewood

    Lakewood Rch, Florida

  • Homestead Associates in Research, Inc.

    Miami, Florida

  • Allied Biomedical Research Institute, Inc

    Miami, Florida

  • Miami Beach Clinical Research Center

    Miami Beach, Florida

  • Theia Clinical Research Centers, LLC

    Tampa, Florida

  • Florida Medical Clinic

    Zephyrhills, Florida

  • Gastroenterology Associates of Central Georgia

    Macon, Georgia

  • Grand Teton Research Group, PLLC

    Idaho Falls, Idaho

  • The University of Chicago

    Chicago, Illinois

  • Indiana University Health University Hospital

    Indianapolis, Indiana

  • Gastroenterology Health Partners, PLLC

    New Albany, Indiana

  • Tri-State Gastroenterology Associates

    Crestview Hills, Kentucky

  • Gastroenterology Health Partners, PLLC

    Louisville, Kentucky

  • Louisiana Research Center - GastroIntestinal Associates

    Shreveport, Louisiana

  • Brigham & Womens Hosp

    Boston, Massachusetts

  • Boston University

    Boston, Massachusetts

  • Allied Gastrointestinal Associates, PA

    Flowood, Mississippi

  • Intercity Gastroenterology

    Fresh Meadows, New York

  • Pioneer Clinical Research NY

    New York, New York

  • Digestive Health Partners, PA

    Asheville, North Carolina

  • Peters Medical Research (PMR), LLC

    High Point, North Carolina

  • Monroe Biomedical Research

    Monroe, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio Gastroenterology Group

    Columbus, Ohio

  • Gastro Intestinal Research Institute of Northern Ohio

    Westlake, Ohio

  • University Gastroenterology

    Providence, Rhode Island

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Gastro One

    Cordova, Tennessee

  • Gastrointestinal Associates of Northeast Tennessee

    Johnson City, Tennessee

  • The University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • GI Alliance

    Garland, Texas

  • TDDC dba GI Alliance Research

    Mansfield, Texas

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.